The motivation is demographic as much as scientific. The United States now counts nearly 60 million residents aged 65 and older, a figure projected to grow by another 42 percent by 2050, when more than 23 percent of Americans will be over 65. Age remains the single strongest risk factor for chronic disease, and for many older adults the burden is compounded by cognitive decline, including Alzheimer’s disease and related dementias. The researchers argue that promoting healthy aging and blunting the impact of age-related disease has become a major national social and economic challenge, one that demands biobehavioral data detailed enough to guide real public health interventions rather than isolated correlations.

To build that dataset, ASHA convenes experts spanning biomedical imaging, integrative physiology, biomechanics and exercise science, neuroscience, behavioral science, social work, public health, and biostatistics. Each participant completes two in-person visits lasting five to eight hours each. The protocol begins with informed consent and questionnaires delivered through Vibrent Health, a secure, HIPAA-compliant online platform that lets people complete medical histories remotely. Those histories cover medications, surgeries, physical activity, smoking, alcohol consumption, menstruation history, fall history, education, marital status, and even zip code, painting a social and environmental backdrop against which the biological measurements can later be interpreted.

The imaging centerpiece is a whole-body MRI protocol performed on a 3 Tesla Siemens MAGNETOM Vida scanner at the university’s Clinical Imaging Research Center, operated by a licensed radiologic technologist with breaks built in for comfort. The brain portion stacks structural and functional sequences: high-resolution T1-weighted MPRAGE anatomy, T2-weighted FLAIR to flag white matter lesions, and diffusion tensor imaging to probe the integrity of neural wiring. Cerebral blood flow is measured at rest with arterial spin labeling, while resting-state and task-based BOLD functional MRI, recorded alongside end-tidal CO2, quantify intrinsic brain networks, cerebrovascular reactivity, and activation during language, motor, and executive function tasks such as picture naming and finger tapping.

The rest of the body gets equal scrutiny. A head-to-toe stack of DIXON images separates water and fat signals to map skeletal muscle size and fat distribution across every anatomical region, while a multi-echo variant quantifies liver fat and iron, key markers for non-alcoholic fatty liver disease and iron overload. Thigh muscle imaging adds quantitative T1, T2, and fat-fraction mapping to detect intramuscular fat infiltration, a hallmark of muscle degeneration. Cardiac MRI rounds out the session with cine imaging of ventricular function, tissue tagging to measure strain, T1 and T2 mapping for fibrosis and edema, diffusion tensor imaging of heart muscle architecture, aortic distensibility and pulse wave velocity as markers of vascular stiffness, 4D flow imaging of aortic hemodynamics, and oxygen-sensitive sequences that probe coronary endothelial function without ever threading a catheter.

On a separate day, after a six-hour fast, participants undergo a vascular battery that spans macro- and microcirculation. Blood pressure is measured sitting, standing, and supine to assess postural regulation; ankle-brachial and toe-brachial indices screen for peripheral artery disease; and the SphygmoCor system derives central pulse wave analysis and pulse wave velocity. Beat-to-beat pressure is captured from a finger cuff via photoplethysmography, and brachial artery flow-mediated dilation, the standard noninvasive test of endothelial health, is measured with Doppler ultrasound and rapid cuff inflation. Near-infrared diffuse correlation spectroscopy over the forearm adds a window into microvascular reactivity and tissue oxygenation kinetics, complementing the larger-vessel measures.

Following an approximately 80-milliliter blood draw, part of which goes to clinical testing and the rest to a biorepository of PAXgene tubes and frozen plasma and serum for future genetic and transcriptomic work, participants refuel with a snack and face a cognitive battery. It includes the Montreal Cognitive Assessment for global screening, the NIH Toolbox Cognition Battery and an odor identification test for domain-specific evaluation, and a prospective memory test probing the ability to act on future intentions cued by the environment. Physical function testing then begins with the Short Physical Performance Battery and grip strength dynamometry, followed by gait analysis on an instrumented ZenoMat walkway under both normal conditions and cognitive load, counting backward by ones or sevens or naming animals while walking. A six-minute walk test and a DEXA scan for lean mass, fat mass, and bone density close the visit.

Between clinic visits, the study follows participants into daily life. For seven days they wear a Fitbit Inspire 3 tracking steps, activity intensity, and sleep stages; a cuffless Hilo bracelet, formerly known as Aktiia, that captures blood pressure fluctuations around the clock; and a FreeStyle Libre continuous glucose monitor sampling interstitial glucose every fifteen minutes. Together these devices record glycemic variability, postprandial responses, nocturnal glucose trends, and autonomic cardiovascular rhythms in real-world settings, adding ecological validity that clinic snapshots cannot provide. The design also builds in safeguards: incidental MRI findings are reviewed by the imaging center’s medical director and communicated to participants with recommendations for follow-up, and the study itself offers no diagnosis or treatment.

What may set ASHA apart most is its deliberate diversity and equity focus. The 600 participants, recruited beginning in November 2024 with completion expected by late 2028, will be evenly distributed across Non-Hispanic Black, Non-Hispanic White, Hispanic or Latino, and Asian residents of Tarrant County, one of the largest and most demographically diverse counties in the country, with balanced sex representation in each group. Concentrating recruitment in a single county trades some generalizability for rigor: the same instruments and personnel assess every participant, minimizing measurement noise. Exclusions screen out active cancer treatment, advanced chronic disease, dementia, non-ambulatory status, severe gait disorders, and other conditions that would confound the healthy-aging signal. The investigators acknowledge the single-site limitation and plan controlled-access data sharing so that qualified researchers elsewhere can test whether the patterns hold. Ultimately, by measuring organ systems in concert rather than isolation, the team hopes to build biological age metrics, from frailty indices to imaging-derived biomarkers, that reveal why some people age with resilience while others decline, and to identify the modifiable factors that keep more of us independent for longer.

Subject of Research: A multidisciplinary community cohort study investigating biological, psychological, and social mechanisms of age-related functional decline through multi-organ imaging and monitoring.

Article Title: The Arlington study of healthy aging: a multidisciplinary community cohort study of functional decline with age

Article References: Davis, D. L., Shah, R., Pixler, L., Mai, D. M., Santos, J., Chandler, C., White, K., Nguyen, J., Moradi, A. S., Choudhari, J., Arena-Marshall, C., Johnson, C., Kamel, L., Liao, Y., Greer, T. L., Cooper, C., Ball, H., Fields, N. L., Wang, X., … Nelson, M. D. (2026). The Arlington study of healthy aging: a multidisciplinary community cohort study of functional decline with age. GeroScience, 48(5), 6409-6420. https://doi.org/10.1007/s11357-026-02498-z

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02498-z

Keywords: healthy aging, cohort study, whole-body MRI, functional decline, vascular function, cognitive aging, wearable monitoring, sarcopenia, biological age, older adults, geroscience, health equity

The review, led by Muhammad Danyal Ahsan and colleagues at Weill Cornell Medicine, was preregistered with PROSPERO and conducted according to the PRISMA 2020 reporting standard. The team searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from their inception through August 2025, screening 18,231 abstracts to identify 17 original research studies published between 2005 and 2024. The studies came from eight countries, with Germany contributing nine of the seventeen, and sample sizes ranged from 22 to 7,287 participants. Critically, the researchers only included studies of people who had no established indication for the scan, excluding patients with known hereditary cancer syndromes, people undergoing cancer staging or recurrence surveillance, and studies that selectively reported results from a single organ system.

The headline numbers are striking. Across the pooled data, only 16.9 percent of scanned individuals had no findings reported, while 78.0 percent had at least one finding. That sounds alarming until the nature of those findings is examined. The most common abnormalities were degenerative spinal disease in 22.0 percent of scans, subcortical cysts in 15.4 percent, and bone marrow edema in 6.2 percent, conditions that are ubiquitous in aging populations and rarely change clinical management when discovered incidentally. The authors estimate that roughly 62 to 67 percent of people undergoing whole-body MRI without a medical indication will receive findings that are not actionable at all.

A smaller but clinically meaningful fraction of scans did flag something requiring attention. Non-malignant actionable findings, defined as non-cancerous abnormalities that prompted laboratory testing, additional imaging, or procedural follow-up, were reported in 14.8 percent of screened individuals. These were most frequently located in the gastrointestinal system, the musculoskeletal system, and the lymphatic or vascular system. The most common specific actionable findings were hepatic steatosis, or fatty liver, in 8.8 percent, pulmonary nodules in 4.8 percent, and uterine fibroids in 4.3 percent. Among the people with such findings, 58.2 percent went on to pursue additional laboratory work or imaging, and 20.8 percent underwent a subsequent procedure such as endoscopy, biopsy, resection, or surgery.

Herein lies the central problem the review exposes: none of the included studies reported the results of that downstream evaluation. Because diagnostic resolution was never documented, the authors could not calculate false-positive rates, overdiagnosis rates, or any measure of whether the follow-up testing ultimately helped or harmed patients. This is a fundamental gap for a screening technology. Screening is only justified when it demonstrably improves clinical outcomes, and the history of medicine is littered with tests that found plenty of abnormalities without extending a single life. Prostate-specific antigen screening and routine diabetes screening in asymptomatic adults, for example, have not proven effective at reducing all-cause mortality, despite detecting real biochemical and metabolic signals.

The cancer detection numbers offer a more nuanced picture. Among the 4,463 participants in the eleven studies that reported pathologically confirmed oncologic outcomes, malignancy was detected in 1.4 percent, with a 95 percent confidence interval of 0.9 to 2.2 percent. The most common cancers found were genitourinary tumors, accounting for 21.8 percent of detections, followed by cancers of the female reproductive system at 19.5 percent and gastrointestinal cancers at 16.5 percent. Notably, the authors point out that roughly 60 percent of the malignancies discovered were in organ systems for which the US Preventive Services Task Force offers no Grade A or B screening recommendation, since current guidelines cover only breast, cervical, colon, and lung cancers. Fewer than 20 percent of US cancers are diagnosed through existing screening programs, which is precisely the gap that multi-organ scanning hopes to fill.

For context, the pooled malignancy yield of whole-body MRI sits within or above the per-examination detection rates of some recommended screening tests. Mammography detects roughly 0.2 to 0.8 percent of cancers per screening round, and colonoscopy detects approximately 0.14 to 0.20 percent. But the authors are careful to emphasize that diagnostic yield alone establishes nothing about clinical benefit. A scan that finds more cancers is not automatically a scan that saves lives; the detected cancers must be ones that would have become lethal without early detection, and the harms of chasing false positives and indolent lesions must be weighed against any mortality reduction. Those calculations simply cannot be made with the current evidence.

The methodological quality of the underlying literature is another major caveat. None of the seventeen included studies was free from risk of bias across all domains when assessed with Joanna Briggs Institute tools, and limitations included concerns about sampling, sample size, and confounding. Statistical heterogeneity between studies was extreme, with I-squared values exceeding 90 percent across most analyses, reflecting differences in the use of contrast agents, diffusion-weighted imaging, vascular protocols, body coverage, thresholds for calling a finding actionable, and outcome definitions. The confidence intervals around the pooled estimates are correspondingly wide; the 95 percent interval for the proportion of scans with any finding spans from 44.9 to 93.9 percent. A funnel plot for the malignancy analyses also showed asymmetry consistent with publication bias or selective reporting, meaning studies that found more cancers may have been more likely to be published.

Generalizability is a further concern. All of the included studies came from non-US healthcare systems in East Asia, Western Europe, and the Middle East, and several involved employer-sponsored, private, or otherwise selected cohorts rather than representative community samples. The pooled cohort was 64.9 percent male, no studies reported race and ethnicity data, and only seven of the seventeen studies explicitly described their populations as asymptomatic. Meanwhile, the commercial landscape that the review is meant to inform is dominated by direct-to-consumer services such as Prenuvo and Function Health, which charge approximately 500 to 3,000 dollars per scan with variable protocols and are often bundled with additional clinical assessments. Marketing campaigns and celebrity endorsements have amplified public interest, yet no professional society, including the American College of Radiology, the USPSTF, or the National Comprehensive Cancer Network, endorses whole-body MRI for the general population.

The authors argue that the technology itself is not the problem; the evidence base is. Whole-body MRI is radiation-free, images multiple organ systems in a single session, and could theoretically address real barriers to preventive care, since organ-specific screening requires multiple visits, is sometimes invasive, and suffers from suboptimal adherence. Advances in artificial intelligence may further reduce acquisition time and standardize interpretation, and the authors suggest that a consensus reporting taxonomy extending the oncologic ONCO-RADS system to cardiovascular, musculoskeletal, and metabolic abnormalities could reduce variability and unnecessary follow-up. But until high-quality observational studies or randomized controlled trials track patients from initial finding through downstream workup to hard outcomes such as morbidity, mortality, overdiagnosis, and cost, the review concludes that most whole-body MRI examinations in people without a medical indication reveal either nothing or nothing that matters, and the clinical value of the scan remains an open question rather than a settled fact.

Subject of Research: Diagnostic yield of whole-body MRI as a multi-disease screening tool in people without an evidence-based indication

Article Title: The Diagnostic Yield of Whole-Body MRI as a Multi-disease Screening Modality: A Systematic Review and Meta-analysis

Article References: Ahsan, M. D., Frontera, N., Gurram, A., Sharaf, S., Qazi, M., Patel, D., Yang, K., Gioia, S., Murray, I. R., McGonigle, R., Guniganti, P., Dodelzon, K., Ma, X., Kierans, A. S., Diamond, L. C., Godwin, K., Shih, G., Sabuncu, M., Lantos, J., … Sharaf, R. N. (2026). The Diagnostic Yield of Whole-Body MRI as a Multi-disease Screening Modality: A Systematic Review and Meta-analysis. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10802-y

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10802-y

Keywords: whole-body MRI, screening, diagnostic yield, meta-analysis, overdiagnosis, cancer detection, incidental findings, preventive medicine, medical imaging, false positives, systematic review, direct-to-consumer health